Literature DB >> 28232480

Heat shock protein 27-derived atheroprotection involves reverse cholesterol transport that is dependent on GM-CSF to maintain ABCA1 and ABCG1 expression in ApoE-/- mice.

Vivek Krishna Pulakazhi Venu1, Ayinuer Adijiang1, Tara Seibert1, Yong-Xiang Chen1, Chunhua Shi1, Zarah Batulan1, Edward R O'Brien2.   

Abstract

Recently, we demonstrated that heat shock protein (HSP)-27 is protective against the development of experimental atherosclerosis, reducing plaque cholesterol content by more than 30%. Moreover, elevated HSP-27 levels are predictive of relative freedom from clinical cardiovascular events. HSP-27 signaling occurs via the activation of NF-κB, which induces a marked up-regulation in expression of granulocyte-monocyte colony-stimulating factor (GM-CSF), a cytokine that is known to alter ABC transporters involved in reverse cholesterol transport (RCT). Therefore, we hypothesized that HSP-27-derived GM-CSF has a potent role in impeding plaque formation by promoting macrophage RCT and sought to better characterize this pathway. Treatment of THP-1 cells, RAW-Blue cells, and primary macrophages with recombinant HSP-27 resulted in NF-κB activation via TLR-4 and was inhibited by various pharmacologic blockers of this pathway. Moreover, HSP-27-induced upregulation of GM-CSF expression was dependent on TLR-4 signaling. Recombinant (r)HSP-27 treatment of ApoE-/- female (but not male) mice for 4 wk yielded reductions in plaque area and cholesterol clefts of 33 and 47%, respectively, with no effect on GM-CSF-/-ApoE-/- mice. With 12 wk of rHSP-27 treatment, both female and male mice showed reductions in plaque burden (55 and 42%, respectively) and a 60% reduction in necrotic core area but no treatment effect in GM-CSF-/-ApoE-/- mice. In vitro functional studies revealed that HSP-27 enhanced the expression of ABCA1 and ABCG1, as well as facilitated cholesterol efflux in vitro by ∼10%. These novel findings establish a paradigm for HSP-27-mediated RCT and set the stage for the development of HSP-27 atheroprotective therapeutics.-Pulakazhi Venu, V. K., Adijiang, A., Seibert, T., Chen, Y.-X., Shi, C., Batulan, Z., O'Brien, E. R. Heat shock protein 27-derived atheroprotection involves reverse cholesterol transport that is dependent on GM-CSF to maintain ABCA1 and ABCG1 expression in ApoE-/- mice. © FASEB.

Entities:  

Keywords:  NF-κB; Toll-like receptors; atherosclerosis; macrophages

Mesh:

Substances:

Year:  2017        PMID: 28232480     DOI: 10.1096/fj.201601188R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

Review 1.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation.

Authors:  Jose A Inia; Edward R O'Brien
Journal:  J Cardiovasc Transl Res       Date:  2020-07-13       Impact factor: 4.132

3.  Heat shock protein-27 and sex-selective regulation of muscarinic and proteinase-activated receptor 2-mediated vasodilatation: differential sensitivity to endothelial NOS inhibition.

Authors:  Vivek Krishna Pulakazhi Venu; Mahmoud Saifeddine; Koichiro Mihara; Mahmoud El-Daly; Darrell Belke; Jonathan L E Dean; Edward R O'Brien; Simon A Hirota; Morley D Hollenberg
Journal:  Br J Pharmacol       Date:  2018-04-25       Impact factor: 8.739

4.  The Candida albicans toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways.

Authors:  Spyridoula-Angeliki Nikou; Chunsheng Zhou; James S Griffiths; Natalia K Kotowicz; Bianca M Coleman; Mary J Green; David L Moyes; Sarah L Gaffen; Julian R Naglik; Peter J Parker
Journal:  Sci Signal       Date:  2022-04-05       Impact factor: 8.192

5.  HSP25 Vaccination Attenuates Atherogenesis via Upregulation of LDLR Expression, Lowering of PCSK9 Levels and Curbing of Inflammation.

Authors:  Yong-Xiang Chen; Chunhua Shi; Jingti Deng; Catherine Diao; Nadia Maarouf; Matthew Rosin; Vipul Shrivastava; Angie A Hu; Sonya Bharadwa; Ayinuer Adijiang; Annegret Ulke-Lemee; Brenig Gwilym; Alexandria Hellmich; Christopher Malozzi; Zarah Batulan; Jonathan L E Dean; F Daniel Ramirez; Jingwen Liu; William T Gerthoffer; Edward R O'Brien
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-01       Impact factor: 10.514

6.  Expression and clinical significance of HSP27 and its phosphorylation in lower extremity arteriosclerosis obliterans.

Authors:  Junqing Bai; Fule Wang; Xuguang Wang; Eerde Mutu; Chen Duan; Yili Qi; Liqiang Hu; Zhanfeng Gao
Journal:  PeerJ       Date:  2020-06-11       Impact factor: 2.984

Review 7.  Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis.

Authors:  Antonio Cervadoro; Roberto Palomba; Giuseppe Vergaro; Roberta Cecchi; Luca Menichetti; Paolo Decuzzi; Michele Emdin; Stefano Luin
Journal:  Front Bioeng Biotechnol       Date:  2018-11-27

Review 8.  Heat Shock Proteins in Vascular Diabetic Complications: Review and Future Perspective.

Authors:  Stefania Bellini; Federica Barutta; Raffaella Mastrocola; Luigi Imperatore; Graziella Bruno; Gabriella Gruden
Journal:  Int J Mol Sci       Date:  2017-12-14       Impact factor: 5.923

9.  Circulating heat shock protein 27 as a novel marker of subclinical atherosclerosis in type 2 diabetes: a cross-sectional community-based study.

Authors:  Xinru Wang; Jie Shi; Bin Lu; Weiwei Zhang; Yehong Yang; Jie Wen; Renming Hu; Zhen Yang; Xuanchun Wang
Journal:  BMC Cardiovasc Disord       Date:  2020-04-25       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.